Vamil Divan, M.D., is a Vice President and Senior Analyst responsible for coverage of the life science tools and diagnostics sector at Credit Suisse Group. He joined the equity research department at Credit Suisse in 2007 as a member of the U.S. pharmaceuticals team. Before joining Credit Suisse, Dr. Divan had worked in the pharmaceutical industry for more than five years at Roche, and then Pfizer Inc. He is a board-certified Internist and was a practicing Physician before he transitioned into the pharmaceutical industry. Dr. Divan holds a medical degree from the University of Buffalo, an MBA from New York University and a B.S. in health care administration and policy from the University of Pennsylvania.
Smaller Companies Filling the Void in Neuroscience Drug Development
October 01, 2020
Unmet Need and Advances in Innovation Make Neuroscience an Area for Growth
March 20, 2020
Diagnostics Display Pricing Power Despite Macro and Regulatory Uncertainty
August 01, 2012